Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

LEX Diagnostics gets FDA nod and CLIA waiver for ultra-fast VELO system

The VELO system supports multiplex testing for Influenza A, Influenza B, and COVID-19, producing PCR results in six to ten minutes

Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI

Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC

Roche appoints Mark Dawson as new Head of Pharma Research and Early Development

Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research

Dewpoint Therapeutics selects groundbreaking MYC development candidate

MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project

AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal

CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform

BioMed X launches groundbreaking AI-driven diabetes research in Barbados

With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease

Pangea Laboratory teams with Gene Solutions to bring AI-driven cancer tests to US patients

Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.

Syngene locks in Bristol Myers Squibb alliance through 2035

The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle